# ClinicalIntelPulse

> Pharmaceutical pipeline and clinical trial intelligence API. Synthesizes 400,000+ registered trials from ClinicalTrials.gov with FDA OpenFDA drug approval data, PubMed literature, and real-time news into institutional-grade intelligence. Used by biotech investors, hedge funds, hospital formulary teams, patient advocacy groups, pharma competitive intelligence teams, and CROs. Pay-per-query via x402 micropayments on Base. Replaces $50,000+/year subscriptions to Evaluate Pharma and Citeline.

## What This Is

ClinicalIntelPulse is a pay-per-query API that gives anyone — human or AI agent — access to the depth of pharmaceutical intelligence that previously required six-figure data subscriptions or a full-time pharma analyst. It covers pipeline scans, regulatory approval outlook, competitive sponsor intelligence, disease landscape analysis, M&A deal signals, global trial coverage, mechanism mapping, failure analysis, and patient trial finding.

Every response is generated by Claude using live data from:
- ClinicalTrials.gov REST API v2 (free, no key — 400,000+ trials globally)
- FDA OpenFDA API (free, no key — NDA/BLA approvals, adverse events)
- PubMed NCBI E-utilities (free, optional free key for higher limits — 35M+ papers)
- Tavily web search (EMA, PDUFA dates, deal news, WHO ICTRP synthesis)

## Payment

All endpoints require x402 micropayment (USDC on Base mainnet).
Protocol: x402 | Network: eip155:8453 | Asset: USDC
Payment address: 0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc

## Endpoints

GET /api/clinical/pipeline-scan?condition={disease}&phase={phase2|phase3|both}&lang={en|es|fr|...}
- Returns: Phase 2/3 trial count, phase 3 highlights, sponsor landscape, geographic distribution, mechanism breakdown, pipeline density assessment
- e.g. condition=Non-Small+Cell+Lung+Cancer | Alzheimer+Disease | Type+2+Diabetes | Crohn+Disease
- Price: $0.15

GET /api/clinical/approval-outlook?condition={disease}&horizon={12m|18m|24m}&agency={FDA|EMA|both}&lang={...}
- Returns: FDA/EMA approval candidates with probability scores, PDUFA action date calendar, breakthrough/fast track/orphan designations, historical success rates by disease area
- Price: $0.25

GET /api/clinical/sponsor-intel?sponsor={company}&focus={pipeline|approvals|deals|all}&lang={...}
- Returns: pipeline by phase, therapeutic area coverage, modality breakdown, FDA approval history, Phase 3 assets with peak sales estimates, partnership activity, investment signals
- e.g. sponsor=Moderna | BioNTech | Alnylam | Vertex+Pharmaceuticals | Regeneron
- Price: $0.20

GET /api/clinical/disease-landscape?condition={disease}&depth={standard|deep}&lang={...}
- Returns: complete pipeline map, approved drug landscape, mechanism landscape (crowded/emerging/gaps), Phase 3 assets with approval probability, PDUFA calendar, deal activity, opportunity score 0-100, investment thesis
- Replaces Evaluate Pharma / Citeline disease reports
- Price: $0.35

GET /api/clinical/trial-brief?nct_id={NCT_ID}&lang={...}
- Returns: trial design, arms, endpoints, eligibility, enrollment, geographic footprint, outcome summary for completed trials
- e.g. nct_id=NCT04368728
- Price: $0.10

GET /api/clinical/mechanism-map?condition={disease}&mechanism={optional}&lang={...}
- Returns: approved mechanisms, pipeline targets by phase, first-in-class opportunities, white spaces, modality breakdown, combination therapy landscape
- Price: $0.20

GET /api/clinical/global-trials?condition={disease}&region={global|africa|asia|europe|latin-america|...}&lang={...}
- Returns: geographic distribution, WHO ICTRP registry coverage (ChiCTR/China, CTRI/India, UMIN/Japan, REBEC/Brazil, ANZCTR/Australia, KCT/Korea, 12 more), EMA/PMDA landscape, unmet needs by region
- Covers neglected tropical diseases, infectious diseases, and conditions with high developing-world burden
- Price: $0.15

GET /api/clinical/failure-analysis?condition={disease}&lang={...}
- Returns: Phase 2→3 and Phase 3→approval success rates, failure taxonomy (wrong hypothesis/patient/endpoint/dose/safety), named failed trials, lessons learned, biomarker strategy
- e.g. Alzheimer's has only 11% Phase 3→approval success rate — this endpoint explains why
- Price: $0.20

GET /api/clinical/patient-finder?condition={disease}&country={optional}&phase={phase2|phase3|any}&lang={...}
- Returns: recruiting trials in plain language, accessible eligibility criteria, step-by-step application guide, questions to ask your doctor, global patient advocacy resources
- Price: $0.10

GET /api/clinical/deal-signal?condition={disease}&deal_type={acquisition|licensing|both}&stage={phase2|phase3|both}&lang={...}
- Returns: acquisition targets with deal value estimates, licensing opportunities, recent deal comps (named transactions), most likely acquirers, deal timing signals, valuation framework
- Price: $0.35

## Language Support

All endpoints support lang parameter: en | es | fr | de | ja | zh | ko | pt | ar | hi

## Discovery

- OpenAPI spec: https://clinicalintelpulse.vercel.app/openapi.json
- Agent discovery: https://clinicalintelpulse.vercel.app/.well-known/agent.json
- LLMs.txt: https://clinicalintelpulse.vercel.app/llms.txt

## Notes for AI Agents

- All endpoints return structured JSON
- NCT IDs must start with "NCT" followed by 8 digits (e.g. NCT04368728)
- No API keys required for underlying data — all handled server-side
- disease-landscape ($0.35) and deal-signal ($0.35) are highest-value for financial analysis
- patient-finder ($0.10) produces plain-language output designed for non-clinical audiences
- Cross-sell: FilingsPulse for biotech SEC filings; PatentPulse for pharma IP landscape